The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being investigated in late-stage clinical trials for the manag...

Full description

Bibliographic Details
Main Authors: McNeel, Douglas G., Bander, Neil H., Beer, Tomasz M., Drake, Charles G., Fong, Lawrence, Harrelson, Stacey, Kantoff, Philip W., Madan, Ravi A., Oh, William K., Peace, David J., Petrylak, Daniel P., Porterfield, Hank, Sartor, Oliver, Shore, Neal D., Slovin, Susan F., Stein, Mark N., Vieweg, Johannes, Gulley, James L.
Format: Online
Language:English
Published: BioMed Central 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5170901/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5170901/

Similar Items